Financial Statements

Novartis AG (NVS)


+0.08 (+0.08%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands , Years are calendar years not fiscal years

Retained Earning Schedule

Year 2022 2021 2020 2019 2018
Retained Earnings (Previous Year) -----
Net Income 6,95524,0218,07211,73212,611
Stock Dividends 551-16,653-1,085-5,087-5,645
Dividend Paid -7,506-7,368-6,987-6,645-6,966
Retained Earnings -----

PPE Schedule

Year 2022 2021 2020 2019 2018
Gross PPE 13,10613,93913,74615,696-
Annual Depreciation 1,7602,1382,77830719,051
Capital Expenditure -2,671-2,971-2,585-2,257-3,355
Net PPE 12,19513,10613,93913,74615,696

Intangible and Goodwill Schedule

Year 2022 2021 2020 2019 2018
Intangible and Goodwill (Previous Year) -35,29426,52429,99929,595
New Purchases -2,702-530-2,130-16,594-34,816
Intangible and Goodwill 35,29426,52429,99929,59529,301

Novartis AG income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Novartis AG FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.